protein

NME1, 1-152aa, Human, Recombinant, E Coli

MBS203362

0.1 mg

310 USD

Recombinant Protein

NME1, 1-152aa, Human, Recombinant, E Coli

NME1

Nucleoside diphosphate kinase A; NDP kinase A; AWD; GAAD; NB; NBS; NDPK-A; NM23; NM23-H1; Non-metastatic cells 1 AWD; drosophila; homolog of; NDPKA; NM23; NM23-M1; Granzyme A activated DNase; GZMA activated DNase; Metastasis inhibition factor nm23; NDK A; NDP Kinase A; NM23 long variant; included; Nonmetastatic protein 23; NME1-NME2 spliced read-through transcript; included; Non-metastatic cells 1; protein (NM23A) expressed in; Nonmetastatic cells 1; protein expressed in; NME1; Nucleoside diphosphate kinase A; Nonmetastatic protein 23; homolog 1; NM23H1B; included; Tumor metastatic process-associated protein.

nucleoside diphosphate kinase A isoform b; Nucleoside diphosphate kinase A; nucleoside diphosphate kinase A; NDP kinase A; granzyme A-activated DNase; metastasis inhibition factor nm23; non-metastatic cells 1, protein (NM23A) expressed in; tumor metastatic process-associated protein; NME/NM23 nucleoside diphosphate kinase 1; Granzyme A-activated DNase; GAAD; Metastasis inhibition factor nm23; NM23-H1; Tumor metastatic process-associated protein

NME1

NME1; NME1; NB; AWD; NBS; GAAD; NDKA; NM23; NDPKA; NDPK-A; NM23-H1; NDPKA; NM23; NDK A; NDP kinase A; GAAD

NDKA_HUMAN

152

MANCERTFIA IKPDGVQRGL VGEIIKRFEQ KGFRLVGLKF MQASEDLLKE HYVDLKDRPF FAGLVKYMHS GPVVAMVWEG LNVVKTGRVM LGETNPADSK PGTIRGDFCI QVGRNIIHGS DSVESAEKEI GLWFHPEELV DYTSCAQNWI YE

> 95% by SDS - PAGE

Liquid. In 20mM Tris-HCl buffer (pH7.5) containing 1mM DTT, 10% glycerol

1 mg/ml (determined by Bradford assay)

Can be stored at 4 degree C short term (1-2 weeks). For long term storage, aliquot and store at -20 degree C or -70 degree C. Avoid repeated freezing and thawing cycles.

SDS-PAGE

Antigen Species: Human

Expression System: E Coli. Endotoxin: < 1.0 Eu per 1 microgram of protein (determined by LAL method)

Cancer

Non-metastatic cells 1 (NME1), also known as NM23-H1, originally identified as a candidate metastasis suppressor gene. NME1 is expressed in different tumor types where their levels have been alternatively associated with reduced or increased metastatic potential. Reductions in NME1 expression have been significantly associated with aggressive behavior in melanoma, breast, colon, and gastric carcinomas. On the contrary, high levels of NME1 gene expression are noted in the advanced stage of thyroid carcinomas. Recombinant human NME1 was expressed in E.coli and purified by using conventional chromatography techniques.

Tee YT., et al. (2006) Taiwan J Obstet Gynecol. 45(2):107-13. Negroni A., et al. (2000) Cell Death Differ. 7(9):843-50.

4557797

NP_000260

NM_000269.2

17.1 kDa (152aa), confirmed by MALDI-TOF.

Adenine Ribonucleotide Biosynthesis, IMP = ADP,ATP Pathway 618580!!Adenine Ribonucleotide Biosynthesis, IMP = ADP,ATP Pathway 468242!!Arf6 Downstream Pathway 138038!!Arf6 Trafficking Events Pathway 137954!!CMP Phosphorylation Pathway 782393!!CMP Phosphorylation Pathway 908070!!E-cadherin Signaling In The Nascent Adherens Junction Pathway 138005!!Guanine Ribonucleotide Biosynthesis IMP = GDP,GTP Pathway 618581!!Guanine Ribonucleotide Biosynthesis IMP = GDP,GTP Pathway 468243!!Integrated Pancreatic Cancer Pathway 711360

This gene (NME1) was identified because of its reduced mRNA transcript levels in highly metastatic cells. Nucleoside diphosphate kinase (NDK) exists as a hexamer composed of 'A' (encoded by this gene) and 'B' (encoded by NME2) isoforms. Mutations in this gene have been identified in aggressive neuroblastomas. Two transcript variants encoding different isoforms have been found for this gene. Co-transcription of this gene and the neighboring downstream gene (NME2) generates naturally-occurring transcripts (NME1-NME2), which encodes a fusion protein comprised of sequence sharing identity with each individual gene product. [provided by RefSeq, Jul 2008]

0.1 mg

310 USD